COSCIENS Biopharma Inc. CSCIF
6.10
0.62
11.31%
as of 25 Sep
- Market cap
- $8.6M
- P/E
- 1.0×
Follow CSCIF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.26 | 0.36 |
P/S ratio |
0.30 | 0.29 | 0.13 | 0.27 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.87) | (1.48) | (0.49) | 4.00 | |
P/B ratio |
0.51 | 0.57 | 0.07 | 0.16 | |
Price to Tangible BV |
0.80 | 1.07 | 0.07 | 0.16 | |
EV/Sales |
(0.69) | (0.68) | (0.49) | (0.33) | |
EV/EBITDA |
0.50 | 0.55 | 0.53 | 0.58 | |
EV/Operating CF |
0.59 | 0.61 | 0.45 | 0.77 | |
EV/FCF |
0.56 | 0.60 | 0.48 | 0.93 | |
Quick Ratio |
2.54 | 2.37 | 4.15 | 3.41 | |
Current Ratio |
3.47 | 3.18 | 5.57 | 4.33 | |
Net Debt/EBITDA |
4.19 | 2.22 | 12.87 | (6.95) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.25 | 0.27 | 0.32 | 0.38 | |
Operating CF/Net income |
0.37 | 0.67 | (0.20) | (2.97) | |
Capex/Depreciation |
0.01 | 0.67 | 0.02 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
35.54% | 67.57% | 9.32% | 4.20% | |
Selling, General and Administrative Expense of Revenue |
141.67% | 145.86% | 71.35% | 37.64% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
(1.42%) | 3.98% | 0.05% | 0.00% | |
Graham Net Nets |
(1.89) | (2.80) | 5.50 | 2.37 | |
Graham Number |
0.00 | 0.00 | 35.97 | 44.79 | |
Earnings Yield |
(574.55%) | (476.26%) | 385.32% | 274.70% | |
Free Cash Flow Yield |
(402.83%) | (391.38%) | (766.41%) | (128.89%) | |
Revenue per Share |
1.40 | 2.10 | 1.80 | 3.00 | |
Operating CF per Share |
(0.64) | (1.39) | (2.08) | 0.57 | |
Capex per Share |
0.00 | 0.18 | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.63) | (1.21) | (2.07) | 0.57 | |
Cash per Share |
8.05 | 6.93 | 4.78 | 5.04 | |
Shareholders Equity per Share |
4.80 | 3.64 | 14.63 | 14.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.80 | 3.64 | 14.63 | 14.17 | |
Free Cash Flow |
(0.67) | (1.28) | (2.17) | 0.60 | |
Working Capital |
9.85 | 7.89 | 7.71 | 7.45 | |
Capital Expenditures |
0.00 | 0.19 | 0.01 | 0.00 | |
Net Current Asset Value |
(4.94) | (6.09) | 5.87 | 5.69 | |
EV/EBIT |
0.48 | 0.49 | 0.46 | 0.46 | |
Capex to Sales |
0.00 | (0.09) | 0.00 | 0.00 | |
Net Profit Margin |
(122.66%) | (98.73%) | 569.76% | (6.43%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.81 | 1.87 | 1.93 | 2.58 | |
Average Payables |
3.38 | 3.31 | 2.82 | 1.93 | |
Average Inventory |
2.53 | 2.00 | 1.78 | 1.39 | |
Average Assets |
33.81 | 28.25 | 24.99 | 23.20 | |
Average Common Equity |
12.55 | 8.50 | 12.73 | 10.97 |
Columns are period end dates